|

JCAR017 (lisocabtagene maraleucel) + ibrutinib Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Juno Therapeutics, a Subsidiary of Celgene1

Indications

  • Lymphoma, Small Lymphocytic1
  • Leukemia, Lymphocytic, Chronic, B-Cell1
  • Cancer1

Birmingham, Alabama1 trial

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

University of Alabama at Birmingham

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.